Oct 2026· Journal of Clinical Medicine· Vol 15, pp. 8076· 0 citations· 35 references
Medicine
TL;DR
In routine care, SGLT2 inhibitor initiation was followed by changes in glycaemic, haematological, uric acid and albuminuria parameters that were similar in direction to those reported in randomised trials; the uncontrolled design and incomplete UACR data preclude causal inference.
Abstract
Background/Objectives: Real-world data are limited for short-term renal and metabolic changes after the initiation of sodium–glucose co-transporter 2 (SGLT2) inhibitors in Turkish clinical practice. We described 1-year changes in these parameters in adults with type 2 diabetes who started treatment with empagliflozin or dapagliflozin. Methods: In this single-centre retrospective cohort (2016–2021; n = 780), paired baseline and 12-month values were compared in patients with available measurements. The urinary albumin-to-creatinine ratio (UACR) was compared with the Wilcoxon signed-rank test. Factors associated with albuminuria response (≥30% UACR reduction) were examined using multivariable logistic regression. Results: HbA1c decreased by 1.0% (95% CI 0.8–1.1; n = 398), haematocrit increased by 1.3 percentage points (n = 418), uric acid decreased by 0.5 mg/dL (n = 221) and eGFR declined by 3.2 mL/min/1.73 m2 (95% CI 2.1–4.2; n = 426). In 109 patients with paired UACR, the median UACR fell from 20.9 [9.0–49.0] to 11.0 [6.0–30.0] mg/g (p < 0.001). A ≥30% reduction occurred in 81.1% of patients with a baseline UACR ≥30 mg/g and 41.7% of patients with a baseline UACR <30 mg/g (adjusted odds ratio: 6.10; 95% CI: 2.24–16.57). Genitourinary infections were more frequent in women as the most common documented reason for discontinuation. Conclusions: In routine care, SGLT2 inhibitor initiation was followed by changes in glycaemic, haematological, uric acid and albuminuria parameters that were similar in direction to those reported in randomised trials; the uncontrolled design and incomplete UACR data preclude causal inference.
Background:
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and dipeptidyl peptidase-4 inhibitors (DPP4i) are commonly used second-line agents in type 2 diabetes mellitus (T2DM). This large-scale real-world analysis compared their effects on major cardiovascular, renal, and diabetes-related complications.
Me...
Sajjad Ahmed Khan, Anurag Marasini· Circulation· 0 citations
Patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) are at high risk for kidney failure and death. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) improve cardiovascular and renal outcomes; yet, their real-world use in patients with diabe...
K. Cohen-Hagai, T. Zitman-Gal, Kalantar-Zadeh Kamyar et al.· Cardiovascular Diabetology· 0 citations
Background/Objectives: Diabetic kidney disease (DKD) and metabolic dysfunction-associated steatotic liver disease (MASLD) frequently coexist in patients with type 2 diabetes mellitus (T2DM) and share common pathophysiological mechanisms. Although atorvastatin has been investigated for potential renal and hepatic effect...
D. D. Ozturk, H. Sumbul, Erdinc Gulumsek et al.· Medicina· 0 citations
Background: Direct real-world comparisons of empagliflozin and canagliflozin regarding renal outcomes in patients with type 2 diabetes mellitus (T2DM) remain limited. This study compared longitudinal changes in the estimated glomerular filtration rate (eGFR) and urinary albumin-to-creatinine ratio (UACR). Methods: This...
Ching-Yao Cheng, Jaw-Horng Liou, Kao Tz Wei et al.· Journal of Clinical Medicine· 0 citations
Background/Objectives: Poor adherence and persistence to sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a critical issue in the treatment of type 2 diabetes mellitus (T2DM), especially in patients with cardiovascular disease (CVD). We aimed to compare...
M. González-González, M. A. Pedrosa-Naudín, D. Fernández-Lázaro et al.· Pharmaceuticals· 0 citations
OBJECTIVE
Sodium-glucose cotransporter 2 inhibitors (SGLT2is) have demonstrated cardiorenal benefits in individuals with type 2 diabetes, but safety data in older adults remain limited. We evaluated the real-world safety of SGLT2is compared with dipeptidyl peptidase 4 inhibitors (DPP-4is) among individuals aged ≥75 yea...
Hanin Harbi, Michael Nesrallah, G. Carney et al.· Diabetes Care· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.